Premium
Use of an ophthalmic formulation of megestrol acetate for the treatment of eosinophilic keratitis in cats
Author(s) -
Stiles Jean,
Coster Martin
Publication year - 2016
Publication title -
veterinary ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.594
H-Index - 50
eISSN - 1463-5224
pISSN - 1463-5216
DOI - 10.1111/vop.12371
Subject(s) - megestrol acetate , cats , medicine , keratitis , eosinophilic granuloma , cytology , eosinophilic , ophthalmology , dermatology , surgery , pathology , cancer
Objective To evaluate a compounded ophthalmic formulation of 0.5% megestrol acetate to treat eosinophilic keratitis in cats. Study design Prospective study. Animals studied Seventeen client owned cats with eosinophilic keratitis in one or both eyes. Methods Eosinophilic keratitis was confirmed by cytology. At each visit, fluorescein staining and photography were performed. Cats were initially treated q 8–12 h with 0.5% megestrol acetate in an aqueous base. Serum glucose was measured at the first or second reexamination. Results Fifteen of 17 (88%) cats had a positive response to treatment, with 6 of 17 (35%) having complete resolution at the first reexamination (2–4 weeks). Two of 17 (12%) cats did not respond to treatment. Most cats required a treatment frequency of once daily to once weekly to maintain remission of disease. No ocular irritation or systemic side effects were noted in any cat. Conclusions and clinical relevance The use of an ophthalmic formulation of 0.5% megestrol acetate is a viable option for treating feline eosinophilic keratitis.